Eligible participants will be randomized to one of two possible groups, one of which will participate by only using the Heartline Study app on their iPhone, while the other will participate by using the study app on their iPhone in addition to obtaining an Apple Watch to use the ECG app and irregular rhythm notification feature.Participation in the study will span a total of three years with two years of active engagement, followed by one year of additional data collection. Anyone who is selected will be able to get a discounted Apple Watch from Best Buy for $49 plus tax. Johnson and Johnson's Heartline study is looking to learn more about the human heart. We believe that this level of flexibility is a better option than any alternative CGM devices with either 7 day, 10 day, or 14 day sensor wear time currently available.”Several similar studies are planned over the course of this year.In addition to its wearable, Nemaura is also developing BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching.Best Buy and GreatCall, a provider of health and safety solutions for older adults and their family caregivers, launched a new Lively App and Lively Wearable2 medical alert device.The Lively App and Lively Wearable2 pair together, giving users access to agents 24/7 who can provide immediate responses and dispatch emergency personnel when the users presses a button on the device, or when a fall is detected. That study aimed to demonstrate the ability of wearables like the Apple Watch to detect heart rate irregularities. Apple Apple During the active engagement period, participants will receive heart health education, wellness tips, surveys, and questionnaires across multiple topics related to overall heart health in the app each week. The goal is for the company to position sugarBEAT as an alternative to traditional CGMs.“Our decision to go head-to-head vs. a hugely successful CGM sensor was based on positive feedback we received from recent meetings with public health insurers in key territories in Europe,” Dr. Faz Chowdhury, CEO of Nemaura, said in a statement.“We believe that most people with diabetes do not currently use any continuous glucose monitoring system due to the high costs and the invasiveness of current products. The gap that we’re looking to fill is to actually help address all those different pollutants that are there in the air and get rid of them.

Healthcare in politics, week 5 Apple is teaming up with Johnson & Johnson and Best Buy to recruit volunteers for a new randomised digital-health study.The three giants of tech, pharma, and retail are partnering for Prior research has already indicated that Apple Watches can spot irregular heartbeats early. Healthcare in politics, week 6

When light shines on the PECO filter, which is produced by LED inside the device, it generates a chemical reaction that breaks down the pollutants.In addition to the new funding, Molekule also announced a new partnership with Lawrence Berkeley National Laboratory, in which the lab studied the effectiveness of the device on eliminating pollutants. We believe that sugarBEAT® changes this paradigm and is the first non-invasive CGM to provide the [masses] an option for daily monitoring whenever they choose at an affordable price point.

"Some of the things that we’ve seen of late, everything from huge amounts of smoke being produced by wildfires to  global pandemics like Coronavirus, which can be spread by airborne droplets, are all set against the backdrop of the larger fight against global air pollution and climate change. This allows patients to be monitored remotely, without constant trips to the doctor, and for physicians to do more timely interventions based on patterns picked up by AI and machine learning.In June, Vator, HP and UCSF Health Hub will be holding an Molekule, which has developed an air purification device that doesn’t just collect pollutants, like traditional filters do, but actually works on a molecular level to get rid of them, raised $58 million in a Series C funding round, bringing its total funding to nearly $100 million.The company sells two consumer devices: the Molekule Air, a standalone device that launched in 2017, which covers about 600 square feet in the home; and the Molekule Air Mini, a smaller device that covers 250 square feet, which the company Molekule's patented air purification technology is called PECO, which is able to destroy pollutants 1,000 times smaller than what high-efficiency particulate air (HEPA) was designed to capture, including VOCs, mold, viruses and bacteria.